Findings from a proof-of-concept phase 2a trial provide preliminary evidence to suggest that dapansutrile, an inhibitor of the NLRP3 inflammasome, may be a promising therapeutic option for gout flares.
Findings from a systematic review published in the International Journal of Rheumatic Diseases confirm that there is currently insufficient evidence to support the efficacy of chloroquine or hydroxychloroquine for the prevention of COVID-19.
The risk for flares during and after pregnancy is low and the severity typically mild in women who have inactive or stable systemic lupus erythematosus in early pregnancy, show data from the PROMISSE study.
Individuals with rheumatoid arthritis are at no more risk for postsurgical complications if they have used a biologic or targeted synthetic DMARD in the weeks preceding surgery than if they had used methotrexate, US research shows.
Advanced knee pain patterns involving constant plus intermittent pain are associated with increased severity of pain and radiographic knee osteoarthritis duration and severity, suggest longitudinal study data.
Denosumab significantly increases bone mineral density in people with glucocorticoid-induced osteoporosis and may be more effective than bisphosphonates, show the results of a systematic review and meta-analysis.
People with symptomatic knee osteoarthritis who undergo physical therapy have greater reductions in pain and functional disability over 1 year than those given intra-articular glucocorticoid injections, randomized trial results suggest.
Findings from RepurpSS-I, a small phase 2a trial, suggest that leflunomide–hydroxychloroquine combination therapy has a favorable safety profile and gives rise to a clinical response in patients with primary Sjögren’s syndrome.
The first report of patients with rheumatic diseases and SARS-CoV2 infection in Italy suggests that people treated with biologic or targeted synthetic DMARDs may not be at increased risk for severe complications from COVID-19.
Rheumatologists highlight that more research needs to be carried out before chloroquine and hydroxychloroquine can be recommended for the treatment of COVID-19, and emphasize the need for adequate supplies of these agents for people with rheumatic diseases.
Immunocompromised patients with autoimmune rheumatic diseases who receive the influenza vaccine have a reduced risk for respiratory-related diseases, according to a longitudinal study published in Rheumatology.